cabozantinib


( Last Updated : January 19, 2023)
Generic Name:
cabozantinib
Project Status:
Pending
Therapeutic Area:
Advanced or metastatic renal cell carcinoma
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0312-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary

Details


Manufacturer Requested Reimbursement Criteria1:
Cabometyx in combination with nivolumab for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Cabometyx in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.